scPharmaceuticals Inc. (SCPH)
NASDAQ: SCPH · Real-Time Price · USD
5.21
+0.13 (2.56%)
At close: Aug 1, 2025, 4:00 PM
5.17
-0.04 (-0.77%)
After-hours: Aug 1, 2025, 4:24 PM EDT

Company Description

scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care.

The company’s lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.

Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector.

The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

scPharmaceuticals Inc.
scPharmaceuticals logo
CountryUnited States
Founded2013
IPO DateNov 17, 2017
IndustryBiotechnology
SectorHealthcare
Employees164
CEOJohn Tucker

Contact Details

Address:
25 Mall Road, Suite 203
Burlington, Massachusetts 01803
United States
Phone617 517 0730
Websitescpharmaceuticals.com

Stock Details

Ticker SymbolSCPH
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001604950
CUSIP Number810648105
ISIN NumberUS8106481059
Employer ID46-5184075
SIC Code2834

Key Executives

NamePosition
John H. TuckerPresident, Chief Executive Officer, Principal Executive Officer and Director
Rachael NokesChief Financial Officer
Michael D. HassmanSenior Vice President of Technical Operations
Katherine TaudvinVice President of Corporate Affairs and Human Resources
Dr. John Mohr Pharm.D.Senior Vice President of Clinical Development and Medical Affairs
Steve C. ParsonsSenior Vice President of Commercial

Latest SEC Filings

DateTypeTitle
Jul 21, 2025SCHEDULE 13G/AFiling
Jun 9, 20258-KCurrent Report
May 14, 202510-QQuarterly Report
May 14, 20258-KCurrent Report
Apr 28, 2025SCHEDULE 13G/AFiling
Apr 21, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 21, 2025DEF 14AOther definitive proxy statements
Mar 19, 2025S-8Securities to be offered to employees in employee benefit plans
Mar 19, 202510-KAnnual Report
Mar 19, 20258-KCurrent Report